Abstract
Left ventricular dilated cardiomyopathy (LV-DCM) refractory to medical management carries a high risk of mortality in the pediatric subgroup. The role of heart transplantation or mechanical circulatory support in treating this subset is limited due to a shortage of donor organs or the potentially life-threatening risks associated with the support devices. This is where reversible pulmonary artery banding (rPAB) steps in as an alternate therapy for treating these patients. This article offers an overview of rPAB in LV-DCM, emphasizing its potential as a significant advancement in pediatric cardiac sciences.